Medical Research Archives
2025
Matthew Halma, Joseph Varón, Sirjana Dhillon et al.
Psychedelic therapies have emerged as a modality of treatment for several treatment resistant diseases, including post-traumatic stress disorder (PTSD), treatment resistant depression, substance use disorders, anxiety, and obsessive-compulsive disorders. Arguably more than with other therapies, their success is dependent on the facilitator and the context of the administration. Several programs...
Current Addiction Reports
2025
Anahita Bassir Nia, Yalda Farahmand, Garret Griffith et al.
Despite national efforts to curb the opioid crisis, the clinical and societal challenges continue to grow. FDA-approved medications for opioid use disorder (OUD) are effective but are associated with high rates of treatment discontinuation and relapse. A collection of agents with acute effects on consciousness, collectively (if variably) categorized as 'psychedelics', have emerged as potential...
Medical Research Archives
2025
Mustafa Zaman, Aseel Aljeshi, Kuragamage Kuraga et al.
1 citation
The use of drugs for recreational purposes has changed dramatically, involving a variety of substances such as opioids, hallucinogens, and cannabinoids. Although these substances are often initially used for recreational purposes, their psychoactive properties can contribute to the development of addiction, withdrawal syndromes, and significant physical and mental health complications. The...
2025
Henrique Tofoli Vieira Machado, Geovana Mendes de Seixas, L. Silva et al.
Introduction: In recent years, psilocybin has been explored as an alternative therapy for neurological and psychiatric disorders, such as depression, anxiety, post-traumatic stress disorder (PTSD), and substance dependence. Studies suggest that when administered under professional supervision, psilocybin can offer relief for patients with treatment-resistant disorders. Objective: The aim of...
Annales pharmaceutiques francaises
2025
Olivier Pierrefiche
Alcohol consumption is a major public health issue. Patients with Alcohol Use Disorder (AUD) can benefit from five treatments that preferentially target membrane receptors, and whose efficacy is generally modest. However, a large body of experimental evidence points to an important role for epigenetics in the effects of alcohol consumption, and epidrugs that modify the epigenome offer an...
American Journal of Psychiatry
2025
Roger S McIntyre, Angela T H Kwan, Rodrigo B. Mansur et al.
23 citations
During the past decade, there has been extraordinary public, media, and medical research interest in psychedelics as promising therapeutics for difficult-to-treat psychiatric disorders. Short-term controlled trial data suggest that certain psychedelics are effective and safe in the treatment of major depressive disorder, treatment-resistant depression, and posttraumatic stress disorder....
Frontiers in Psychiatry
2025
Human-Friedrich Unterrainer
4 citations
This essay employs the Icarus myth as a metaphor to examine the role of transcendence in addiction. Icarus' disregard for boundaries, driven by his quest for transcendence, mirrors the behavior of individuals with addictive tendencies. Addiction, a chronic disorder marked by compulsive substance use or behaviors, is characterized by loss of control, tolerance, withdrawal, and life disruptions....
PLoS One
2025
Masume Bakhtiari, Mojtaba Habibi Asgarabad, Fahimeh Dehghani et al.
6 citations
Adolescents with Internet addiction (IA) frequently encounter elevated levels of anxiety and depression, which subsequently results in the perpetuation of their addiction behaviors. Mindfulness-based cognitive therapy for children (MBCT-C) is an adapted version of traditional MBCT that targets emotional problems in children. The present study aimed to provide a framework for the implementation...
PLoS One
2025
Jizhao Li, Dongling Wang, Shuang Bai et al.
6 citations
Mindfulness-based Tai Chi Chuan (MTCC) have been shown to contribute to improvements in cognitive and executive functions. Changes in inhibition, an aspect of executive function, have been closely linked to mobile phone addiction. However, the relationship between these elements remains unclear. This study aims to investigate the effects of an 8-week MTCC intervention on executive function,...
Frontiers in Psychology
2025
Diane Joss, Joseph Rosansky, Paula Gardiner et al.
1 citation
Adverse childhood experiences (ACE) are transdiagnostic developmental risk factors for various mental and physical health issues, including Opioid Use Disorder (OUD). Existing research demonstrated ACE not only affects the onset, severity, and comorbidity of disorders, but also affects treatment responses. To investigate whether and how ACE modulates treatment effects of Mindfulness Based...
International review of neurobiology
2025
Caitlin M. DuPont, Matthew W. Johnson
6 citations
The current chapter presents the literature evaluating the effects of classic psychedelic treatments on five substance use disorders: alcohol, tobacco, opioid, stimulant, and cannabis. Most work on psychedelics and substance use disorders was conducted for alcohol use disorder. A range of classic psychedelics (LSD, psilocybin, and ayahuasca) appear to be beneficial for facilitating both reduced...
Journal of Psychopharmacology
2025
Gianmarco Ingrosso, Anthony J. Cleare, Mario F Juruena
20 citations
Ketamine has demonstrated both rapid and sustained efficacy in treating depression, especially in treatment-resistant cases. However, concerns regarding the addictive potential of ketamine during long-term depression treatment persist among clinicians. This review aimed to summarise the evidence on addiction phenomena associated with ketamine treatment of depression. A comprehensive search was...
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
2025
Jordi Jornet-Plaza, Sandra Ledesma-Corvi, M Julia García-Fuster
6 citations
While ketamine was approved for treatment-resistant depression in adult patients, its efficacy and safety profile for adolescence still requires further characterization. In this context, prior preclinical studies have shown that sub-anesthetic doses of ketamine during adolescence exert antidepressant-like effects in rodents in a dose- and sex-dependent manner. However, additional studies...
Therapeutic advances in drug safety
2025
Carlos Roncero, Milton Merizalde-Torres, Néstor Szerman et al.
11 citations
In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years. As the S-enantiomer of ketamine, esketamine's dosing guidelines and strict...
Frontiers in Psychiatry
2025
Mary R. Shen, Dylan E Campbell, Anika Kopczynski et al.
10 citations
Opioid use disorder (OUD) continues to be a public health crisis in the United States, with mortality having doubled over the last twenty years, leading to significant economic cost, morbidity, and mortality. This has caused significant demand for novel therapeutics. Preliminary evidence demonstrates that ketamine may be helpful in treating OUD as well as serve as an adjunct during treatment of...
American Journal of Psychiatry
2025
Noam Goldway, Snehal Bhatt, Stephen Ross et al.
23 citations
PAT elicited durable shifts in personality, suggesting normalization of abnormal personality trait expression in AUD. Further study is needed to clarify whether PAT exerts its beneficial effects by reducing impulsiveness or whether impulsive individuals inherently respond better to PAT.